- Home
- NRXP vs ACHL Comparison
NRXP vs ACHL Comparison
Compare NRXP & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- ACHL
- Stock Information
- Founded
- NRXP 2015
- ACHL 2016
- Country
- NRXP United States
- ACHL United Kingdom
- Employees
- NRXP N/A
- ACHL N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRXP Health Care
- ACHL Health Care
- Exchange
- NRXP Nasdaq
- ACHL Nasdaq
- Market Cap
- NRXP 51.3M
- ACHL 46.0M
- IPO Year
- NRXP N/A
- ACHL 2021
- Fundamental
- Price
- NRXP $2.28
- ACHL $1.38
- Analyst Decision
- NRXP Strong Buy
- ACHL Buy
- Analyst Count
- NRXP 3
- ACHL 2
- Target Price
- NRXP $31.67
- ACHL $4.00
- AVG Volume (30 Days)
- NRXP 464.9K
- ACHL 1.9M
- Earning Date
- NRXP 03-27-2025
- ACHL 04-03-2025
- Dividend Yield
- NRXP N/A
- ACHL N/A
- EPS Growth
- NRXP N/A
- ACHL N/A
- EPS
- NRXP N/A
- ACHL N/A
- Revenue
- NRXP N/A
- ACHL N/A
- Revenue This Year
- NRXP N/A
- ACHL N/A
- Revenue Next Year
- NRXP N/A
- ACHL N/A
- P/E Ratio
- NRXP N/A
- ACHL N/A
- Revenue Growth
- NRXP N/A
- ACHL N/A
- 52 Week Low
- NRXP $1.10
- ACHL $0.63
- 52 Week High
- NRXP $7.33
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- NRXP 38.85
- ACHL 72.41
- Support Level
- NRXP $2.80
- ACHL $1.10
- Resistance Level
- NRXP $3.07
- ACHL $1.41
- Average True Range (ATR)
- NRXP 0.29
- ACHL 0.02
- MACD
- NRXP -0.10
- ACHL 0.00
- Stochastic Oscillator
- NRXP 2.52
- ACHL 90.48
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.